机构：[1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[2]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.[3]Department of Respiratory Medicine, Changsha Hospital Affiliated to Xiangya Medical College, Central South University (The First Hospital of Changsha), Changsha, China.[4]Department of Respiratory and Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou, China.[5]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.临床科室肿瘤内科河北医科大学第四医院[6]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属协和医院[7]Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属协和医院[8]Department of Thoracic Oncology, Cancer Center, Shanxi Bethune Hospital, Taiyuan, Shanxi, China.山西白求恩医院[9]Department of Internal Medicine-Oncology, Inner Mongolia People's Hospital, Huhehot, Inner Mongolia, P.R. China.[10]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fuzhou, China.[11]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
KRAS mutations are common in non-small cell lung cancer (NSCLC) and are associated with patient prognosis; however, targeting KRAS has faced various difficulties. Currently, immunotherapy, chemotherapy, and chemoimmunotherapy play pivotal roles in the first-line treatment of KRAS-mutated NSCLC. Here, we summarize the current evidence on first-line therapies and compare the treatment outcomes and biomarkers for different regimens. KRAS inhibitors and other emerging alternative treatments are also discussed, as combining these drugs with immunotherapy may serve as a promising first-line treatment for KRAS-mutated NSCLC in the future. We hope that this review will assist in first-line treatment choices and shed light on the development of novel agents for KRAS-mutated NSCLC.
基金：
The study is supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-C-054).
第一作者机构：[1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
通讯作者：
推荐引用方式(GB/T 7714)：
He Qi,Liu Xiaoyan,Jiang Liyan,et al.First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives[J].Cancer Biology & Therapy.2025,26(1):2441499.doi:10.1080/15384047.2024.2441499.
APA：
He Qi,Liu Xiaoyan,Jiang Liyan,Liu Ping,Xuan Weixia...&Wang Mengzhao.(2025).First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Cancer Biology & Therapy,26,(1)
MLA：
He Qi,et al."First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives".Cancer Biology & Therapy 26..1(2025):2441499
